Summary
Boston Scientific Corporation (BSX) has filed an 8-K detailing the completion of a significant debt offering. On February 27, 2024, the company's wholly owned finance subsidiary, AMS Europe, successfully closed an offering of €2,000,000,000 in senior notes. This offering consists of €750,000,000 of 3.375% Senior Notes due 2029 and €1,250,000,000 of 3.500% Senior Notes due 2032. The notes are fully and unconditionally guaranteed by Boston Scientific Corporation, providing investors with direct credit risk to the parent company. The primary stated use of the net proceeds, approximately €1.980 billion, is to finance the previously announced acquisition of Axonics, Inc. While the debt issuance is a critical step, the acquisition is contingent on certain closing conditions and timelines. The filing also outlines a provision for special mandatory redemption of these notes at 101% of their principal amount plus accrued interest if the Axonics acquisition is not consummated by a specified date or if the company decides not to pursue it. Excess proceeds not used for the acquisition may be used for general corporate purposes, including the repayment of maturing senior notes.
Key Highlights
- 1Boston Scientific (BSX) completed a €2 billion senior notes offering via its subsidiary AMS Europe on February 27, 2024.
- 2The offering comprises €750 million in 3.375% notes due 2029 and €1.25 billion in 3.500% notes due 2032.
- 3The notes are fully and unconditionally guaranteed by Boston Scientific Corporation.
- 4Net proceeds of approximately €1.980 billion are intended to finance the acquisition of Axonics, Inc.
- 5A special mandatory redemption clause exists: if the Axonics acquisition does not close by a specified deadline (potentially January 2026), the notes must be redeemed at 101% of principal plus accrued interest.
- 6The offering was conducted under a shelf registration statement on Form S-3.
- 7The company also mentioned potential use of proceeds for the repayment of its 3.450% senior notes due March 2024 and general corporate purposes if not fully allocated to the acquisition.